Dermatology Licensing Deal Calculator —
benchmark your deal in 60 seconds
Phase 2 dermatology deals median ~$40M upfront, ~$500M total. IL-13 and TYK2 programs are seeing 2x premiums. Built on 1,900+ verified biopharma transactions across 12 therapeutic areas.
Dermatology deal benchmarks at a glance
Median deal terms for dermatology licensing transactions, by development phase. Data current as of 2026.
| Phase | Median Upfront | Median Total Value | Median Royalty (Tiered) |
|---|---|---|---|
| Preclinical | $15M | $400M | 3–7% |
| Phase 1 | $35M | $700M | 4–9% |
| Phase 2 | $100M | $1.6B | 6–12% |
| Phase 3 | $300M | $3.5B | 9–17% |
Source: Ambrosia Benchmarker dataset, 1,900+ verified transactions (2017–2026). Primary sources: SEC EDGAR 8-K filings, FTC premerger notifications, ClinicalTrials.gov.
Recent comparable deals
- Pfizer–Arena ($6.7B etrasimod)
- BMS–Forbius
- AbbVie–Cerevel
Why Dermatology is priced this way
IL-13, IL-17, IL-23, JAK inhibitors, and TYK2 dominate inflammatory dermatology. Atopic dermatitis is the largest indication driver; psoriasis is consolidating around branded biologics.
Try it live
Run a Dermatology deal scenario
Pick your phase, modality, and indication. Get instant benchmark ranges — no signup needed to start.
Quick Benchmark
Live data from 1,900+ deals. Select your parameters:
Dermatology licensing — frequently asked
What is the median upfront payment for a Dermatology licensing deal?
How are Dermatology deal milestones structured?
What royalty rates are typical for Dermatology licensing?
Is there a free Dermatology deal calculator?
How does Dermatology licensing compare to other therapeutic areas?
7-Day Free Trial · No Promo Code
Run unlimited dermatology deals — Pro.
Monte Carlo sensitivity, partner matching across 850+ companies, scenario comparison (Bear/Base/Bull rNPV), and board-ready PDF reports. Free for 7 days. Cancel anytime.
Then $299/month · No charge during trial · Cancel anytime